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Abstract
Background: Data regarding comorbidities of hepatitis C virus infection (HCV) in the kingdom of Saudi Arabia
(KSA) are lacking. The present study aimed to determine the prevalence and risk factors of HCV among Saudi
patients with diabetes mellitus (DM) in Dammam, KSA.
Methods: In this cross-sectional study done in 2011, a total of 1054 Saudi DM patients were randomly selected
from the Diabetes Center in Dammam Medical Complex, KSA, for interview and HCV screening using the HCV
Rapid Test. Positive cases were later confirmed via INNO-LIA HCV score line immune assay.
Results: Seropositivity of HCV was 1.9 %. DM duration of >5 years increased the probability of HCV risk to 3.7 fold
while insulin users were 3.2 times more likely to have HCV infection. Increased hospital admission (3–4 times) also
increased HCV risk by 11.5 times and 13.6 times among patients with ≥5 admissions. Similarly, having 3–4 surgical
procedures increased HCV risk by 8.6 times and 39.3 times with ≥5 procedures. HCV transmission is 4 times more
likely by blood transfusion. Those who shared personal items were 8.5 times more likely to have HCV. Tattooing
increased HCV risk by 6.7 times. The likelihood of HCV infection was also higher among DM patients with liver
diseases and elevated liver enzymes.
Conclusion: The study confirmed a significant association between HCV risk and DM. Frequency of HCV among
DM Saudis was 1.9 %. Predictors of HCV among DM patients were sharing personal items, occupational exposure to
blood or its products, elevated transaminases, tattooing, disease duration > 5 years, increased hospital admission
and blood transfusion.
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Background
Diabetes mellitus (DM) is a global public health threat.
In 2014, more than 387 million cases reported world-
wide and is expected to rise by as much as 592 million
by 2035 [1].
Hepatitis C virus (HCV) infection is another world-
wide major health problem affecting more than 170 mil-
lion, with 80 % harboring chronic infection. It is a major
cause of morbidity, mortality and is a main risk factor
for acute hepatitis and chronic liver diseases including
cirrhosis, liver cancer, and chronic kidney disease [2].
There are increasing reports indicating an association
between HCV and type 2 DM (T2DM). In controlled
studies, individuals with HCV were observed to have in-
creased T2DM risk [3, 4] and T2DM patients have at
least a 2-fold greater risk of HCV infection [3, 5]. HCV
induces impaired insulin signaling, insulin resistance
(IR), disturbed glucose, protein and lipid metabolism as
well as hepatic steatosis [6, 7]. It has been suggested that
the associations between DM, HCV, IR and steatosis cu-
mulatively increases risk of progression to hepatic fibro-
sis and hepatocellular carcinoma as well as reduce
virological response to interferon-α-based therapy [7].
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In the Kingdom of Saudi Arabia (KSA), DM is as a
major public health problem with alarming rates [8].
Data regarding co-morbidity with HCV are lacking. The
study therefore aims to determine the frequency and risk
factors of HCV among Saudi patients with DM.
Methods
The present cross-sectional study was undertaken last
2011. Target population was all known DM patients at-
tending the Diabetes Center in the Dammam Medical
Complex, Dammam, KSA. A random sample of consent-
ing Saudi patients were selected every other day to be
included in the study. Response rate was 100 %. Enrolled
patients were interviewed in privacy by the investigators
using a generalized questionnaire that includes socio-
demographic characteristics, intravenous drug use, fam-
ily history for DM and other medical histories. History
of previous exposure to possible risk factors for HCV in-
fection (at least 6 months prior to interview) were also
collected. Weight and height were measured and noted.
A drop of whole blood per patient was collected by
the investigators from the blood samples drawn for rou-
tine lab investigations. Following the manufacturer’s in-
structions, blood was tested for HCV antibodies
(qualitative detection) using “The Hepatitis C Virus
Rapid Test Device” (whole blood/serum/plasma) [ACON
Laboratories, Inc. San Diego, CL, USA]. This test has an
accuracy of 99.3 %, sensitivity of 99 % and specificity of
98.6 %. Patients with positive results were referred to the
hospital central lab for confirmation via INNO-LIA
HCV score line immune assay [Innogenetics, Belgium].
Confirmed HCV patients were referred to Hepatology
department for management.
Patient records were obtained after the laboratory re-
sults of the routine lab investigations performed at the
date of the interview [serum levels of liver enzymes; ala-
nine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) and creatinine] were released. Levels of
these markers were judged based on the upper limit of
the reference normal range according to the used kits.
High lipid profile was defined as >200 mg/dl for choles-
terol, >150 mg/dl for triglycerides, >130 mg/dl for low-
density lipoprotein cholesterol (LDL-C) [9]. Cut off for
low level high density lipoprotein cholesterol (HDL-C)
was <50 mg/dl for females and 40 mg/dl for males [9].
Glycemic control was classified into uncontrolled if
HbAc1 ≥ 7 % and controlled if HbAc1 < 7 % [10]. The
available findings of abdominal ultrasonic examination
were also recorded.
Body mass index (BMI) was calculated as the ratio of
the weight (kg) to the height(m)2 then classified as under-
weight (<18.5 kg/m2), normal (18.5–< 25 kg/m2), over-
weight (25–< 30 kg/m2), grade I obese (30–< 35 kg/m2),
grade II obese (35–< 40 kg/m2) and grade III obese
(≥40 kg/m2) [11].
Statistical analysis
Data were analyzed using SPSS version 16.0 (SPSS Inc.
Chicago, IL, USA) and the Epi-info (CDC, Atlanta, GA)
[Open Source Epidemiologic Statistics for Public Health,
Version 2.3.1. www.OpenEpi.com, updated 2011/23/06,
accessed 2012/06/14]. The mean, standard deviation, me-
dian, odds ratio corresponding 95 % confidence interval
(95 % CI) were computed. Chi-square and Student’s t-test
were the used tests of significance. Logistic regression ana-
lysis was carried out using all measured variables to iden-
tify the relationship with other variables. The regression
analysis was performed using the Enter method. A P value
of <0.05 was considered statistically significant. Only sig-
nificant predictors were presented with odd ratios and
95 % confidence intervals. Non-significant predictors with
p-values >0.05 were not presented.
Results
General characteristics
The present study included 1057 Saudi DM patients
(32.2 % males and 67.8 % females). The mean age of en-
rolled patients was 48.42 ± 13.70 year (min = 12, max =
87 years). At least 4.1 % of the subjects were minors (10–19
years) and 5.0 % were 20–29 years old. Adults between 30
and 39 years were 11.8 %. The largest proportion (79.1 %)
of patients were 40 years old and above. Majority of the pa-
tients were married (91.8 %). More than 40 % were illiterate
and 47.2 % attended schools. Only 5.0 % were university
graduates or higher. Majority (74.9 %) were unemployed
and were non-smokers (81.93 %). Overall, 89 % of DM
patients were either overweight or obese (BMI ≥25 kg/m2;
n = 1028).
Disease profile
DM duration ranged from 1 month to 45 years (9.88 ±
7.84 years). T2DM was the most common (92.2 %). Pa-
tients were treated with insulin (27.3 %), oral
hypoglycemic drugs (56.8 %), combination drugs (9.8 %),
or just with diet control (6.1 %). Glycemic control was
achieved by 64.3 % of patients whereas 35.7 % were un-
controlled. Most patients (76.1 %) had a positive family
history of DM.
History of exposure to risk factors for HC
Of the 969 married patients, 3.2 % had a partner with
known HCV. Exposure to dental procedure was given by
57.7 % of the patients. Sharing personal items such as
shaving devices/tooth brushes were reported by 2.3 % of
patients. A small proportion received a type of injection.
The majority of patients (81.9 %) were previously hospital-
ized at least once in their lifetime with a mean of 1.7 ± 1.4
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(min = 1, max = 9) admissions. Two thirds of patients
(66.2 %) reported 1 to 8 surgical procedures (1.4 ± 0.8).
Half (50.0 %; n = 646) of married women had a history of
abortion. Recipients of blood transfusion were 17.5 %. A
minority (0.8 %) were on dialysis and 0.3 % (n = 3) had a
previous diagnosis of hepatitis B infection. Liver diseases
(other than HCV) were reported by 3.3 %. Only 1.3 % of
patients were exposed to blood or its products in occupa-
tional settings. Tattooing was reported by 1.8 %.
Women were more likely to be exposed to HCV risk fac-
tors than men. Women were 4.5 times (Confidence Interval
(CI) = 1.3–15.1) more likely to have a husband with HCV.
They were also more exposed to dental procedures [Odds
Ratio (OR) 10.9 (CI = 8.1–14.9)], hospitalization [OR 1.7
(CI = 1.3–2.4)] and surgical procedures [OR 2.0 (CI = 1.5–
2.6)]. The probability was also higher among women with
history of blood transfusion [OR 3.4 (CI = 2.2–5.3)], injec-
tions [OR 18.0 (CI = 4.4–73.9)] and intravenous drug use
[OR 32.1 (CI = 4.4–232.4)]. On the other hand, men were
4.4 times (CI = 1.9–10.3) more likely to share personal
items. No differences were observed regarding glycemic
control, occupational exposure to blood or its products, tat-
tooing, dialysis, history of hepatitis B or other liver diseases.
Clinical laboratory and imaging findings
Laboratory results revealed both increased serum trans-
aminases among 5.8 % and creatinine among 8.2 % of
patients. Abnormal lipid profile was observed in 40.6 %
patients with high serum cholesterol, 35.8 % with high
triglycerides, 39.7 % with high LDL-cholesterol and
47.9 % with low HDL-cholesterol. Abnormal abdominal
ultrasound was reported by 105 out of 210 participants
that suggested fatty liver (49.5 %) and liver cirrhosis
(0.5 %).
Prevalence of HCV
Using the Rapid screening test, 22 (2.1 %) of the patients
were found to be seropositive for HCV. On applying
confirmatory test, only 20 cases were true positive
resulting in a frequency of 1.9 % without significant dif-
ference between type 1 and type 2 DM.
Risk factors for HCV
Patients who tested positive for HCV (51.6 ± 11.7 years)
were older than those who tested negative (48.36 ±
13.73 years). Table 1 shows that DM duration >5 years in-
creased the risk of ’ HCV 3.7 folds (CI = 1.1–12.7). Insulin
users were 3.2 times (CI = 1.3–8.1) more likely to have
HCV than non-users. The frequency of hospitalization
and surgical procedures were significantly associated
with HCV risk. Those who were admitted to hospital
3–4 times were 11.5 times (CI = 1.4–94.4) more likely
to have HCV and the risk increases to 13.6 (CI = 1.5–
123.9) if admitted >5 times. Similarly, surgical
procedures increased the risk for HCV by 8.6 folds
(CI = 1.7–44.2) with 3–4 procedures and 39.3 folds
(CI = 3.1–495.0) with ≥5 procedures than those who
never had surgery. Blood transfusion quadruples (OR =
4.0, CI = 1.6–9.8) the probability of HCV infection. Those
who shared personal items with others were 8.5 times
(CI = 2.3–31.4) more likely to have HCV than those
who didn’t. Tattooing also increased the risk of HCV
to 6.7 folds (CI = 1.4–31.0). The likelihood of HCV is
also higher among DM patients with other liver dis-
eases (OR = 19.4; 95 % CI = 7.2–52.4) and elevated
liver enzymes (OR = 12.3; 95 % CI = 4.8–31.5).
Significant independent predictors of HCV among pa-
tients are shown in Table 2 (non-significant predictors were
not presented). These include sharing articles (OR = 27.5,
CI = 5.4–140.0), exposure to blood or its products in occu-
pational setting (OR = 23.8, CI = 2.2–257.7), elevated liver
enzymes (OR = 19.1, CI = 6.0–61.1), tattooing (OR=,
CI = 7.7 (1.4–44.0), diseases duration >5 years (OR =
6.8, CI = 1.5–31.5), hospitalization >2times (OR = 4.7,
CI = 1.6–13.6), and blood transfusion (OR = 3.67, CI =
1.2–11.0) This model classifies correctly 98.5 % of cases.
Discussion
There is evidence that DM patients are at higher risk of
acquiring HCV infection and may be related to either
the disease itself or frequent parenteral exposure [12].
However, some controlled studies failed to support this
hypothesis [13]. The prevalence rate of HCV (1.9 %) in
the present study is much lower than the 36 % reported
from Pakistan [12] and 11 % reported from Nigeria [14].
It is also lower than the rates reported in France, UK
and USA, which ranged from 3 % to 8 % [3, 15, 16].
However the rate revealed by the present study is com-
parable to the 1.3 % reported from Tunisia [14] and the
1.65 % reported in Greece [17].
The rate of HCV among blood donors in the central
blood bank of Dammam was taken as control. The
screening of 10,853 apparently healthy blood donors
during the year of study identified only 8 confirmed
cases of HCV (0.074 %) [Obtained from blood bank re-
cords through personal communication]. As for the
whole Eastern province, the catchment area of Dammam
Diabetes Center, the recorded rate of HCV among blood
donors was 0.59 % (79 out of 13,443 during 2001) [18].
According to the Ministry of Health, 299 (0.011 %) cases
of HCV have been reported in the same region
(2,776,046 inhabitants) in 2011 [19]. Hence, the present
study provides evidence of the higher likelihood of HCV
infection among DM patients.
The reported HCV cases in KSA are low (0.0–0.02 %, in
2011) [19] and declining [18–20], probably due to routine
screening of blood donors, low prevalence of intravenous
addiction and wide practice of infection control procedures
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Table 1 Distribution of Patients and HCV risk
Factor Positive to HCV Negative to HCV OR (95 % CI) X2 (P value)
No % No %
Sex:
Malea 5 25.0 335 32.3 1.4 (0.5-4.0) 0.48 (0.49)
Female 15 75.0 702 67.7
Marital status:
Married 20 100.0 949 91.5 0.98 (0.97-0.99) 1.85 (0.25)b
Non marrieda 0 0.0 88 8.5
Employment:
Yesa 2 10.0 263 25.4 3.1 (0.7-13.3) 2.47 (0.088)b
No 18 90.0 774 74.6
Type:
Type I 3 15. 0 79 7.6 2.1 (0.6-7.5) 1.49 (0.20)b
Type IIa 17 85.0 958 92.4
Insulin Treatment:
Yes 13 65.0 380 36.6 3.2 (1.3-8.1) 6.76 (0.009)*
Noa 7 35.0 657 63.4
Glycemic control status: 0.97 (0.4-2.5) 0.004 (0.950)
Controlleda 13 65.0 667 64.3
Uncontrolled 7 35.0 370 35.7
Duration of disease:
>5 years 17 85.0 826 60.6 3.7 (1.1-12.7) 4.93 (0.019)b*
≤5 yearsa 3 15.0 409 39.4
Hepatitis C partner:c( (n = 969)
Yes 1 5.0 30 3.2 1.6 (0.2-12.4) 0.214 (0.482)b
Noa 19 95.0 919 96.8
Occupational exposure:
Yes 1 5.0 13 1.3 4.2 (0.5-33.3) 2.11 (0.236)b
Noa 19 95.0 1024 98.7
Dental procedure: 0.9 (0.4-2.2) 0.061 (0.804)
Yes 11 55.0 599 57.76
Noa 9 45.0 438 42.24
Injection: 0.7 (0.1-5.5) 0.096 (1.000)b
Yes 1 5.0 70 6.8
Noa 19 95.0 967 93.2
IV Drug Use: 0.8 (0.1-6.3) 0.034 (1.000)b
Yes 1 5.0 62 6.0
Noa 19 95.0 975 94.0
Hospitalization:
Yes 19 95.0 847 81.7 4.3 (0.6-32.0) 2.352 (0.151)b
Noa 1 5.00 190 18.3
Number of admissions:
0a 1 5.0 190 18.3
1–2 times 8 40.0 675 65.1 2.3 (0.3-18.1) 0.614(0.692)
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among medical personnel. Nevertheless, it should be noted
that intravenous addiction is still a major factor for HCV
transmission and as such, patients who confide such infor-
mation should be further investigated to track and identify
other users who are potential carriers of HCV. Socioeco-
nomic development, mass education and increased aware-
ness of the disease also played a role [20, 21] in keeping the
prevalence of HCV at bay.
Table 1 Distribution of Patients and HCV risk (Continued)
3–4 times 7 35.0 116 11.2 11.5 (1.4-94.4) 8.047 (0.007)*
5+ times 4 20.0 56 5.4 13.6 (1.5-123.9) 8.825 (0.012)*
Surgery:
Yes 17 85.0 683 65.9 2.9 (0.9-10.1) 3.21 (0.094)b
Noa 3 15.0 354 34.1
Number of operations:
0a 3 15.0 354 34.1 2.40 (0.7-8.5) 1.97(0.195)
1–2 times 13 65.0 639 61.6 8.6 (1.7-44.2) 9.50(0.020)*
3–4 times 3 15.0 41 4.0 39.3 (3.1-495.0) 21.07 (0.044)*
5+ times 1 5.0 3 0.3
Abortion:d(n–646)
Yes 9 69.2 314 49.6 2.3 (0.7-7.5) 1.96 (0.262)
Noa 5 30.8 319 50.4
Blood Transfusion:
Yes 9 45.0 176 17.0 4.0 (1.6-9.8) 10.68 (0.001)*
Noa 11 55.0 861 83.0
Sharing personal items:
Yes 3 15.0 21 2.0 8.5 (2.3-31.4) 14.89 (0.009)b*
Noa 17 85.0 1016 98.0
Tattoo:
Yes 2 10.0 17 1.6
Noa 18 90.0 1020 98.4 6. 7 (1.4-31.0) 7.77 (0.048)b*
Liver disease:
Yes 7 35.0 28 2.7 19.4 (7.2-52.4) 63.94 (<0.001)*
Noa 13 65.0 1009 97.3
Elevated liver enzymes: (n = 1015)
Yes 8 40.0 51 5.1 12.3 (4.8-31.5) 43.55 (<0.001)*
Noa 12 60.0 944 94.9
Positive US finding:(n = 210)
Yes 1 16.7 104 51.0 0.2 (0.02-1.7) 2.75 (0. 212)b
No a 5 83.3 100 49.0
Elevated creatinine: (n = 1024)
Yes 3 15.8 81 8.1 2.1 (0.6-7.5) 1.48 (0.200)b
Noa 16 84.2 924 91.9
Dialysis:
Yes 1 5.0 7 0.7 7.7 (0.9-66.1) 4.89 (0.142)b
Noa 19 95.0 1030 99.3
Total 20 100 1037 100
aReference category
bExact test
cCalculated for married (n = 969)
dEach category was tested against reference category; Calculated for females (n = 646); *Statistically significant
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In the present study, sharing personal items that may
be contaminated with infected blood and tattooing were
defined as HCV predictors. The risk of HCV continues
to be a great occupational threat [22]. In agreement, ex-
posure in occupational setting among the studied pa-
tients was a predictor for HCV. Failure to adhere to
universal precautions promote exposure to potentially
infectious body fluids [22]. Consequently, blood transfu-
sion was also identified as a predictor of HC [17, 23] as
well as increased hospital admission [24]. In the present
work, HCV risk was significantly associated with both
hospitalization and frequency of surgical operations. Par-
allel findings were previously observed [23]. These
suggest a nosocomial source of HCV infection in chron-
ically admitted DM patients.
In agreement with prior investigators [4, 13] who
observed increased HCV positivity with increasing
age, patients positive for HCV were older than those
who tested negative. The higher frequency in older age
may be explained by more exposure to risk factors [5].
The studied women had a higher rate of seropositivity
compared to men. Ndako et al. [14] recorded the same
finding, while others observed a significant association
of HCV with male sex [4, 5]. The present finding may
be explained by the current significant female pre-
dominance regarding exposure to blood transfusion,
hospitalization, surgical interference, parenteral injec-
tions and dental therapy which are known risk factors
for HCV and may be related to their gynecological or
obstetric history.
Consistent with Sotiropoulos et al. [17], the present
study did not show an association between HCV and the
type of DM, unlike the studies done by Jadoon et al. [5],
Ndako et al. [8] and Ali et al. [12] who demonstrated a
link between HCV and T2DM. Higher infection among
insulin users may be linked to more frequent exposure
to insulin injections and finger sticks for monitoring
blood glucose [10] where unsafe injections or sharing
contaminated equipment promote infection [2]. In con-
trast, Rudoni et al. [15] reported a negative association
between HC, mode of treatment and use of finger stick
devices in hospitalized patients.
Association between chronicity of DM and HCV in
the studied patients may reflect increased exposure for
HCV infection [8, 20]. Other studies didn’t support this
finding [13, 17]. HCV had no association with glycemic
control status in the present study whereas increased
risk of HCV was associated with good control in some
studies [5] and with poor control in others [13].
Chronic elevations of transaminases are common in
both DM and HCV even without clinical manifestations
in the liver [16, 25]. In the present study, elevated trans-
aminases were a predictor for HCV infection, reflecting
that HCV infection maybe responsible for liver function
abnormality. Consistent findings were observed in other
studies [16, 17]. Hence, screening for HCV among DM
patients can be conducted using liver function tests.
The authors acknowledge some limitations. The pre-
dictors of HCV in the present cohort, while identified
based on statistical significance had wide confidence in-
tervals and therefore should be interpreted with caution.
Nevertheless, these risk factors are in agreement with
several other epidemiologic data and therefore still has
enough clinical precision to make decisions on how best
to proceed if such HCV risk factors are present in every
patient. Further information may still be needed.
Conclusion
The study confirmed a higher rate and a significant as-
sociation between HCV and DM in Saudi patients in
Dammam, KSA. The present study recommends
screening for HCV among DM patients with elevated
serum transaminases or those having DM for >5 years.
HCV awareness and prevention campaign for all
chronic DM patients are encouraged.
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